Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …

Adenosine signalling has long been a target for drug development, with adenosine itself or
its derivatives being used clinically since the 1940s. In addition, methylxanthines such as …

The adenosine A1 receptor (A1R) is a promising therapeutic target for non-opioid analgesic
agents to treat neuropathic pain,. However, development of analgesic orthosteric A1R …

In the 10 years since our previous International Union of Basic and Clinical Pharmacology
report on the nomenclature and classification of adenosine receptors, no developments …

Upon receipt in the dorsal horn (DH) of the spinal cord, nociceptive (pain-signalling)
information from the viscera, skin and other organs is subject to extensive processing by a …

Four adenosine receptors have been cloned and characterized from several mammalian
species. The receptors are named adenosine A1, A2A, A2B, and A3. The A2A and A2B …

Adenosine is involved in a range of physiological and pathological effects through
membrane-bound receptors linked to G proteins. There are four subtypes of adenosine …

Caffeine causes most of its biological effects via antagonizing all types of adenosine
receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons …

This review is focused on purinergic neurotransmission, ie, ATP released from nerves as a
transmitter or cotransmitter to act as an extracellular signaling molecule on both pre-and …

Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the
world. There is growing evidence that they could also be promising therapeutic targets in a …